๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer : Results from Cancer and Leukemia Group B Study 90006

โœ Scribed by Joel Picus; Susan Halabi; W. Kevin Kelly; Nicholas J. Vogelzang; Young E. Whang; Ellen B. Kaplan; Walter M. Stadler; Eric J. Small; for Cancer; Leukemia Group B

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
184 KB
Volume
117
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A Phase II study of estramustine, doceta
A Phase II study of estramustine, docetaxel, and carboplatin with granulocyteโ€“colony-stimulating factor support in patients with hormone-refractory prostate carcinoma : Cancer and Leukemia Group B 99813
โœ William K. Oh; Susan Halabi; W. Kevin Kelly; Cary Werner; Paul A. Godley; Nichol ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 98 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND The authors determined the safety and efficacy of estramustine, docetaxel, and carboplatin with granulocyteโ€“colonyโ€stimulating factor (Gโ€CSF) support in patients with hormoneโ€refractory prostate carcinoma. ## METHODS In the current multicenter, cooperative group study,

A phase 2 study of carboplatin plus doce
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel
โœ Robert W. Ross; Tomasz M. Beer; Susanna Jacobus; Glenn J. Bubley; Mary-Ellen Tap ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Prostate cancer is the second leading cause of cancer mortality among men in the U.S. To the authors' knowledge, there is no proven, effective, secondโ€line therapy for docetaxelโ€refractory disease. Recent data suggest that platinum salts may be effective when combined wi